Analytical Data
-
Gene name
IL-13Rα1
-
简介
Interleukin 13 receptor subunit alpha 1 is a subunit of the interleukin 13 receptor. Interleukin 13 receptor subunit alpha 1 has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4. IL-13R alpha 1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived IL-13R alpha 1 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Biological Activity
Measured by its binding ability in a functional ELISA. When recombinant rat IL-13R alpha 1 at 4 µg/mL (100 µL/well) can bind recombinant human IL-13. The ED50 for this effect is 25.58 ng/mL. Measured by its binding ability in a functional ELISA. When recombinant rat IL-13R alpha 1 at 4 µg/mL (100 µL/well) can bind recombinant human IL-13 .The ED50 for this effect is 25.58 ng/mL.
-
Alternative Names
Interleukin-13 receptor subunit alpha-1; IL-13R-alpha-1; IL-13RA1; CT19; CD213a1; IL13R
-
Species
Rat
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 95% as determined by reducing SDS-PAGE. as determined by SDS-PAGE.
-
Uniprot
Q561K3
-
Expression Region
T27-T342
-
AA Sequence
TEVQPPVTNLSVSVENLCTIVWTWSPPEGASPNCSLRYFSHFDDQQDKKIAPETRRKKELPLNEKICLQVGSQCSTNESEKPSPLVKKCISPPEGDPESAVTELQCIWHNLSYMKCSWLPGKNTSPDTNYTLYYWYSSLGKSLQCENIHREGQHIGCSFKLTKVESNYEHHNIQIMVKDNAGKIRPSYKIVSFTSNVKPGPPHIKHLFLKNGALFVQWKNPQNFSSRCLSYEVEVNSTQTDSYNSNSLEVEEDKCQNSEFDRNMEGASCFISPGVLANTVYTVRVRVKTNKLCFDDNDLWSNWSEALSIGKEPNST
-
Protein Length
Partial
-
Molecular Weight
90 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-13 receptor subunit alpha-1 (IL-13Rα1) is a key player in the signaling pathways of interleukin-13 (IL-13), a cytokine involved in various biological processes, including immune response and inflammation. Abnormal IL-13 signaling is implicated in a range of diseases, particularly allergic conditions such as asthma, as well as fibrosis in organs like the lungs and liver. The IL-13Rα1 protein is known to form a functional receptor complex with IL-4Rα, enabling the modulation of cellular responses in immune cells. Due to its pivotal role in mediating the effects of IL-13, IL-13Rα1 has emerged as a potential therapeutic target for treating asthma and other IL-13 related disorders. Researchers have focused on developing recombinant IL-13Rα1 proteins to study their structure, function, and interactions with IL-13 and IL-4. These studies are essential for understanding the molecular mechanisms underlying IL-13 signaling and the development of new therapeutic strategies. Additionally, recombinant IL-13Rα1 could serve as a valuable tool in the development of novel antibodies or inhibitors, potentially leading to improved treatments for inflammatory diseases. Overall, the investigation of IL-13Rα1 recombinant proteins holds significant promise for advancing our understanding of IL-13-related pathologies and developing innovative treatment options.
